Therapeutic Use: : Ulcer
Branded Name : WeiKe'an(R)
NDC : 0083
Strength : 7 Cap*1
Package Size : 40mg
Pantoprazole is a proton pump inhibitor drug that inhibits gastric acid secretion.
Pantoprazole is metabolized in the liver by the cytochrome P450 system. Metabolism mainly consists of demethylation by CYP2C19 followed by sulfation. Another metabolic pathway is oxidation by CYP3A4. Pantoprazole metabolites are not thought to have any pharmacological significance. Pantoprazole is relatively free of drug interactions;however, it may alter the absorption of other medications that depend on the amount of acid in the stomach, such as ketoconazole or digoxin. Generally inactive at acidic pH of stomach, thus it is usually given with a pro kinetic drug. Pantoprazole suppresses the secretion of acid. As it binds irreversibly to the pumps, new pumps have to be made before acid production could be resumed. The drug's plasma half-life is about 2 hours.
Pantoprazole is used for short-term treatment of erosion and ulceration of the esophagus caused by gastroesophageal reflux disease. Initial treatment is generally of eight weeks' duration, after which another eight week course of treatment may be considered if necessary.It can be used as a maintenance therapy for long term use after initial response is obtained.
This medication may affect the results of certain lab tests, such as drug screenings (pantoprazole can cause a false positive for THC, the psychoactive component of cannabis.
Merro Pharmaceutical Co., Ltd.
Merro Pharmaceutical Co., Ltd. is a public listed company specializing in R&D, manufacturing and marketing of pharmaceutical products, with registered capital of 350 million yuan, which covers a land of 155,000 square meters and the built-up area is 130,000 square meters. "Merro" is rated as the famous trademark of China and it is a national high-tech enterprise.
Merro has been devoted to the development, manufacture and sales of chemical medicine, biological medicine, Chinese traditional medicine and herbal medicine and Merro is a leading company in the pharmaceutical field. Merro’s core strategies are: developing and manufacturing of National Essential Drugs, Generic drugs and Biomedicines; focusing on ER preparation and biologicals; collaborating widely with international pharmaceutical markets; improving the company’s innovation capability and becoming an international pharmaceutical company with high technology, superior service and adaptability to changes.
Merro has all the manufacturing equipment and analytical instrument up to worldwide standard. Merro represents a Brand that enjoys nationwide reputation among the professionals and consumers for the quality. Merro pursues partners worldwide for new products and technology to evolve into a company with specialty, standardization and worldwide presence. Merro has more than 300 employees with technical background and more than 100 on pharmaceutical certifications, majority of whom enjoys decent English proficiency. This provides the foundation for the overseas business strategy. Besides, the company has also been rewarded more than 30 honors, such as “Excellent Enterprise in National Pharmaceutical Industry”. Merro will assure more responsibility to society and promote the common prosperity of the company and the community.